Titlebook: Antimicrobial Resistance; A Crisis in Health C Donald L. Jungkind,Joel E. Mortensen,Gary B. Calan Book 1995 The Editor(s) (if applicable) a

Mirage

Emerging Trends in Antimicrobial Resistance: A Laboratory Perspective, patients,. but also challenges laboratory testing practices and procedures. To effectively meet these challenges laboratorians must realize the important role they assume in the midst of this “resistance crisis” and re-evaluate their goals and responsibilities regarding provision of susceptibility

LUCY

foppish

Charlatan

Practical Management of Patients Infected with Resistant Organisms: An Infection Control Perspectivtrains of .. However, in the 1970s and early 1980s, multi-drug resistant Gram-negative bacilli became the major problem confronting hospital-based infectious diseases clinicians and infection control programs.. More recently, methicillin-resistant . (MRSA) and vancomycin-resistant enterococci have e

phlegm

Oration

Molecular Approaches to the Spreading Problem of Drug Resistant Malaria,fically stained malaria parasites, and he reasoned that the dye might have potential as an antimalarial treatment. When a 21 year old man with fever, chills, a headache and parasites in his blood failed to improve after a week of observation, Erlich began daily infusions of 0.5g of methylene blue. T

Obvious

IRATE

Antifungal Drugs and Resistance,inistered. Because it was the only option, and because systemic mycoses were relatively infrequent, there was little interest in understanding the mechanism of action of amphotericin B, or expanding options for antifungal therapy. The advent of AIDS and our increasing use of broad spectrum antibacte

Respond

Vancomycin-Dependent Enterococci: A Clinical and Laboratory Assessment,solation of strains of . and . demonstrating specific requirements for glycopeptide antimicrobial agents.. In this chapter, the clinical and laboratory features and proposed mechanism of vancomycin-dependence of the first of these isolates, strain TJ310, is described in detail, and the available inf

synovitis

Antifungal Drugs and Resistance,lopment of resistance on the part of some fungal pathogens. From amphotericin B we have expanded to multiple new classes of drugs, with multiple alternatives within those classes. However, we have still not reached the optimal agents which are fungicidal, minimally toxic, and can be administered eit